Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 1/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | MC4R | P32245 | 1/20 | 0.38 |
| ▸ | MC5R | P33032 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1086470 | 0.90 | FAAH (0.42) | TACR2TACR1KMT2AFAAHGRM2 | |
| SCHEMBL4486191 | 0.87 | MMP13 (0.40) | TACR2TACR1KMT2AFAAHGRM2 | |
| SCHEMBL1086782 | 0.83 | TACR2 (0.42) | TACR2TACR1GRM2 | |
| SCHEMBL1086672 | 0.83 | KDM4E (0.44) | TACR2TACR1KMT2AFAAHMMP13 | |
| SCHEMBL1086488 | 0.83 | KDM4E (0.42) | TACR2TACR1KMT2AFAAHSIGMAR1 | |
| SCHEMBL1086846 | 0.82 | TSHR (0.43) | TACR2TACR1FAAHGRM2SIGMAR1 | |
| SCHEMBL1086756 | 0.82 | CCR3 (0.42) | TACR2TACR1GRM2MMP13HDAC1 | |
| SCHEMBL1086247 | 0.82 | GPR119 (0.45) | TACR1HDAC1 | |
| SCHEMBL1086489 | 0.80 | ALDH1A1 (0.46) | KMT2AHDAC1 | |
| SCHEMBL1086354 | 0.80 | SIRT2 (0.42) | TACR2TACR1FAAHGRM2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105290-A1 | Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-Compounds and the Use Thereof for Producing Drugs | GRUENENTHAL GMBH (DE) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105290-A1 | Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-Compounds and the Use Thereof for Producing Drugs | DDO, DAO, OTC | TACR2 1923/4885TACR1 1796/4885KMT2A 4267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.